Drug Profile
Tranexamic acid - Palisade Bio
Alternative Names: LB-1148; Tranexamic acid - Leading BioSciences; TXALatest Information Update: 11 Aug 2023
Price :
$50
*
At a glance
- Originator Leading BioSciences
- Developer Leading BioSciences; Palisade Bio
- Class Amines; Anti-infectives; Anti-inflammatories; Antifibrinolytics; Antihaemorrhagics; Cardiovascular therapies; Cyclohexanecarboxylic acids; Skin disorder therapies; Small molecules
- Mechanism of Action Antifibrinolytic agents; Serine protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Postoperative ileus
- Phase II Cardiogenic shock; Post-surgical adhesions; Septic shock
- No development reported Hypovolaemic shock
Most Recent Events
- 09 Aug 2023 Efficacy and adverse events data from a phase II PROFILE trial in Post surgical adhesion released by Palisade Bio
- 05 Jul 2023 Palisade Bio completes enrolment in its dose optimization trial in healthy volunteers
- 11 May 2023 Palisade Bio initiates enrolment in a dose optimization trial in healthy volunteers